Hemoglobin S Disease
Health Information Search Results
Peer Reviewed Scientific Research Reports.
|<< Prev 20 ||Showing 1 to 11 of 11 Matches||Next 20 >>|
1. The genomics of new drugs in sickle cell disease.
Match Strength: 4.970
The quality of life of patients with sickle cell disease in developed countries has improved significantly over the past two decades. Currently available measures to prevent the painful crises and the complications of the disease include the use of penicillin prophylaxis, antipneumonococcal vaccine, folate administration, chronic red cell transfusions in patients with cerebrovascular disease, iron chelating agents, fetal hemoglobin-enhancing agents, such as hydroxyurea, decitabine and butyrate, drugs that augment the endogenous nitric oxide levels and agents that restore red cell dehydration. ... Read More »
» Published in Pharmacogenomics. 2006 Sep;7(6):909-17.
2. The KDOQI clinical practice guidelines and clinical practice recommendations for treating anemia in patients with chronic kidney disease: implications for nurses.
Match Strength: 4.902
The National Kidney Foundation Kidney Disease Outcomes Quality Initiative recently published revised clinical practice guidelines and recommendations for the treatment of anemia. This article provides an overview of the new guidelines and recommendations, with a focus on the hemoglobin treatment range, iron status, use of erythropoiesis-stimulating agents, and adjuvant therapies. Publication Types: Practice Guideline, Research Support, Non-U.S. Gov ... Read More »
» Published in Nephrol Nurs J. 2006 Jul-Aug;33(4):423-6, 445; quiz 427-8.
3. Risk factors for vascular complications in patients on peritoneal dialysis.
Match Strength: 4.597
The major cause of death in patients on peritoneal dialysis (PD) is vascular complications, including congestive heart failure, cerebrovascular disease, and myocardial infarction. To clarify the risk factors for vascular complications in patients on PD, we investigated the clinical course of PD in patients with and without cardiovascular and cerebrovascular complications. From among 327 end-stage renal disease (ESRD) patients initiated onto PD from April 1995 to March 2005 in the Kidney and Dialysis Center, Saitama Medical School, 8 developed de novo cardiovascular and cerebrovascular ... Read More »
» Published in Adv Perit Dial. 2006;22:192-7.
4. Intravenous iron does not affect the rate of decline of residual renal function in patients on peritoneal dialysis.
Match Strength: 3.284
The preservation residual renal function (RRF) is important for adequacy of peritoneal dialysis. Oxidative stress from intravenous (IV) iron has been shown to cause renal damage. The effect of IV iron on RRF has not been studied. Here, we report our experience during April 1999-March 2005 of the effect of IV iron on RRF. The study group included 24 patients (9 men, 15 women). The mean age of the group was 61 +/- 17.7 years. Diabetes mellitus and hypertension were the underlying cause of end-stage renal disease in 55% of the patients. We found serum creatinine, creatinine clearance, urea ... Read More »
» Published in Adv Perit Dial. 2006;22:99-103.
5. Prevalence and treatment of anemia with once-weekly epoetin alfa in patients with diabetes and chronic kidney disease.
Match Strength: 3.127
OBJECTIVE: To describe the characteristics and prevalence of anemia in patients with diabetes and chronic kidney disease (CKD) not receiving dialysis and to evaluate the efficacy and safety of once-weekly (QW) epoetin alfa for the treatment of anemia in these patients. METHODS: Post hoc subset analyses were conducted for 2 studies: a prospective, multicenter survey evaluating the prevalence of anemia in patients with CKD (the Prevalence of Anemia in Early Renal Insufficiency [PAERI] study) and a prospective, multicenter, open-label trial evaluating the efficacy and safety of QW epoetin alfa ... Read More »
» Published in Endocr Pract. 2006 Sep-Oct;12(5):506-13.
6. Predictive factors for cytomegalovirus infection after orthotopic liver transplantation using an ultrasensitive polymerase chain reaction assay.
Match Strength: 2.942
The predictive factors for cytomegalovirus (CMV) infection in de novo liver transplant patients were determined at 3 months posttransplantation. We included all consecutive patients except those who died or who had lost their graft within 1 month posttransplant. We recorded both donor (D) and recipient (R) data. Immunosuppression utilized tacrolimus, steroids, with or without mycophenolate mofetil, and/or induction therapy with anti-CD25 monoclonal antibodies. CMV prophylaxis was administered only to those at high risk of CMV infection, namely, D+/R- patients. These cases received intravenous ... Read More »
» Published in Transplant Proc. 2006 Sep;38(7):2339-41.
7. HNF4alpha and NF-E2 are key transcriptional regulators of the murine Abcc6 gene expression.
Match Strength: 2.911
Mutations in an ABC transporter gene called ABCC6 are responsible for pseudoxanthoma elasticum (PXE), a rare heritable disease characterized by elastic fiber calcification in skin, ocular and vascular tissues. The presumed function of this ABC transporter is to export metabolites from polarized cells. However, the endogenous substrate(s) are unknown and the exact relationship with elastic fibers is unclear. As ABCC6 is only expressed at high level in liver and kidneys, tissues seemingly unrelated to the PXE phenotype, we explored the transcriptional regulation of the murine Abcc6 gene to ... Read More »
» Published in Biochim Biophys Acta. 2006 Aug-Sep;1759(8-9):426-36. Epub 2006 Aug 11.
8. Perioperative management of peritoneal dialysis patients: review of abdominal surgery.
Match Strength: 2.842
On abdominal computed tomography scan for evaluation of hematuria, the index patient, a 23-year-old male, was found to have multiple renal cysts bilaterally. He had been on peritoneal dialysis for 6 years, complicated by intermittent episodes of exit-site infection and peritonitis. Over time, he developed recurrent urinary tract infection and nephrolithiasis with intermittent hematuria. His maintenance dose of recombinant erythropoietin was discontinued, and he maintained a normal hemoglobin level. Annual surveillance of the bilateral renal cysts with magnetic resonance imaging revealed ... Read More »
» Published in Adv Perit Dial. 2006;22:119-23.
9. Preclinical evaluation of Hematide, a novel erythropoiesis stimulating agent, for the treatment of anemia.
Match Strength: 2.614
OBJECTIVE: To evaluate the preclinical erythropoiesis stimulating properties of Hematide, a novel, PEGylated, synthetic peptide for the treatment of anemia associated with chronic kidney disease and cancer. METHODS: The in vitro activity of Hematide was assessed in competitive binding, proliferation, signal transduction, and apoptosis assays, and in erythroid colony-forming assays with CD34(+) cells purified from human bone marrow. Erythropoiesis and pharmacokinetics were evaluated in rat, monkey, and a rat chronic renal insufficiency (CRI) model following single administration. Erythropoiesis ... Read More »
» Published in Exp Hematol. 2006 Oct;34(10):1303-11.
10. Is a prophylactic treatment by erythropoietin relevant to reduce red blood cell transfusion in the pediatric intensive care unit?
Match Strength: 2.544
OBJECTIVE: An adult trial reported the efficacy of recombinant human erythropoietin in critically ill patients with a 19% decrease in red blood cell transfusion. Our aim was to evaluate the relevance of this prophylactic treatment in children hospitalized in a pediatric intensive care unit (PICU). DESIGN: Cohort study from January 1995 to December 2004. SETTING: University hospital PICU. PATIENTS: Children between 1 month and 18 yrs of age. INTERVENTIONS: We searched through a prospective databank for all children hospitalized in the PICU for > or =4 days (potential recipients of ... Read More »
» Published in Pediatr Crit Care Med. 2006 Nov;7(6):541-4.
11. Exenatide: a new option for the treatment of type 2 diabetes.
Match Strength: 2.303
OBJECTIVE: To evaluate available literature characterizing the pharmacology, pharmacokinetics, drug interactions, efficacy, and safety of exenatide in patients with type 2 diabetes. DATA SOURCES: A PubMed database search (1966-May 2006) was conducted, using exenatide as the search term. The manufacturer's prescribing information was also used. STUDY SELECTION AND DATA EXTRACTION: English-language articles were selected and data were extracted with a focus on clinical outcomes associated with the treatment of patients with type 2 diabetes. DATA SYNTHESIS: Exenatide exerts a glucoregulatory ... Read More »
» Published in Ann Pharmacother. 2006 Oct;40(10):1777-84. Epub 2006 Sep 19.
|<< Prev 20 ||Showing results 1 to 11 of 11||Next 20 >>|
* All information on Level1Diet.com is for educational purposes only. These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease. Before changing your diet, or adding supplements to your diet, or beginning an exercise program, everyone should consult a qualified and licensed health practitioner; a physician, dietician or similar professional.